Prevalence of Doping Use in Elite Sports: A Review of Numbers and Methods

Sports Medicine

Volumn 45, Issue 1, 2015, Pages 57-69

  de Hon, Olivier ^a   Kuipers, Harm ^b   van Bottenburg, Maarten ^c  

^a Anti Doping Authority The Netherlands   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATHLETIC PERFORMANCE; CHEMICAL ANALYSIS; DOPING; EGO; HUMAN; PREVALENCE; PSYCHOLOGY; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA;

ATHLETIC PERFORMANCE; CHEMISTRY TECHNIQUES, ANALYTICAL; DOPING IN SPORTS; EGO; HUMANS; PREVALENCE; QUESTIONNAIRES;

EID: 84920067690     PISSN: 01121642     EISSN: 11792035     Source Type: Journal    
DOI: 10.1007/s40279-014-0247-x     Document Type: Review

References (110)

1. USADA. U.S. postal service pro cycling team investigation. Colorado Springs, United States of America: United States Anti-Doping Agency; 2012.
2. Sorgdrager W, van Bottenburg M, Goedhart E. Joining or Quitting [Original Title: ‘Meedoen of Stoppen’]. Arnhem, The Netherlands; 2013.
3. WADA. WADA seeks stakeholder feedback on Working Group Report: lack of effectiveness of testing programs. Montreal, Canada 2013 [30 May 2013]; Available from: http://playtrue.wada-ama.org/news/wada-seeks-stakeholder-feedback-on-working-group-report-lack-of-effectiveness-of-testing-programs/?utm_source=rss&utm_medium=rss&utm_campaign=wada-seeks-stakeholder-feedback-on-working-group-report-lack-of-effectiveness-of-testing-programs.
4. Laure P. Epidemiologic approach of doping in sport. A review. J Sports Med Phys Fitness. 1997;37(3):218–24.
5. Hatton CK. Beyond sports-doping headlines: the science of laboratory tests for performance-enhancing drugs. Pediatr Clin North Am. 2007;54(4):713–33 (xi).
6. Lentillon-Kaestner V, Ohl F. Can we measure accurately the prevalence of doping? Scand J Med Sci Sports. 2011;21(6):e132–42.
7. D’Angelo C, Tamburrini C. Addict to win? A different approach to doping. J Med Ethics. 2010;36(11):700–7.
8. Kayser B, Mauron A, Miah A. Viewpoint: legalisation of performance-enhancing drugs. Lancet. 2005;366(Suppl 1):S21.
9. Kayser B, Mauron A, Miah A. Current anti-doping policy: a critical appraisal. BMC Med Ethics. 2007;8:2.
10. McNamee MJ, Tarasti L. Juridical and ethical peculiarities in doping policy. J Med Ethics. 2010;36(3):165–9.
11. Savulescu J, Foddy B, Clayton M. Why we should allow performance enhancing drugs in sport. Br J Sports Med. 2004;38(6):666–70.
12. Berning JM, Adams KJ, Stamford BA. Anabolic steroid usage in athletics: facts, fiction, and public relations. J Strength Cond Res. 2004;18(4):908–17.
13. Jenkins PJ. Growth hormone and exercise: physiology, use and abuse. Growth Horm IGF Res. 2001;11(Suppl A):S71–7.
14. WADA. The 2013 Prohibited List International Standard. Montreal, Canada: World Anti-Doping Agency; 2012.
15. WADA. Laboratory testing figures. Montreal, Canada 2012 [30 May 2013]; Available from: http://www.wada-ama.org/en/Science-Medicine/Anti-Doping-Laboratories/Laboratory-Testing-Figures/. Accessed 11 July 2014.
16. Bowers LD. The analytical chemistry of drug monitoring in athletes. Annu Rev Anal Chem (Palo Alto Calif). 2009;2:485–507.
17. Catlin DH, Fitch KD, Ljungqvist A. Medicine and science in the fight against doping in sport. J Intern Med. 2008;264(2):99–114.
18. Lentillon-Kaestner V. The development of doping use in high-level cycling: from team-organized doping to advances in the fight against doping. Scand J Med Sci Sports. 2013;23(2):189–97.
19. Voet W. Prikken en slikken [original title: Massacre a la chaine]. Roeselare: Roularta Books NV; 1999.
20. IOC. IOC disqualifies four medallists from Athens 2004 following further analysis of stored samples. Lausanne, Switzerland 2012 [30 May 2013]; Available from: http://www.olympic.org/news/ioc-disqualifies-four-medallists-from-athens-2004-following-further-analysis-of-stored-samples/184931.
21. CNN. Ramzi stripped of Olympic 1500 m gold. Atlanta, USA 2009 [30 May 2013]; Available from: http://www.cnn.org/2009/SPORT/11/18/athletics.olympics.ramzi.doping/index.html.
22. Le Ressiot D. Mensonge Armstrong [The Armstrong Lie]. L’Equipe. 2005;2005:23.
23. Verroken M. Ethical aspects and the prevalence of hormone abuse in sport. J Endocrinol. 2001;170(1):49–54.
24. Bahr R, Tjornhom M. Prevalence of doping in sports: doping control in Norway, 1977–1995. Clin J Sport Med. 1998;8(1):32–7.
25. Palmer W, Taylor S, Wingate A. Adverse analyzing—a European study of anti doping organization reporting practices and the efficacy of drug testing athletes. Switzerland: UNI Global Union; 2011.
26. Strano Rossi S, Botre F. Prevalence of illicit drug use among the Italian athlete population with special attention on drugs of abuse: a 10-year review. J Sports Sci. 2011;29(5):471–6.
27. van der Merwe PJ, Kruger HS. Drugs in sport—results of the past 6 years of dope testing in South Africa. S Afr Med J. 1992;82(3):151–3.
28. Maquirriain J. Epidemiological analysis of doping offences in the professional tennis circuit. J Occup Med Toxicol. 2010;5:30.
29. Pluim B. A doping sinner is not always a cheat. Br J Sports Med. 2008;42(7):549–50.
30. Zorzoli M, Rossi F. Implementation of the biological passport: the experience of the International Cycling Union. Drug Test Anal. 2010;2(11–12):542–7.
31. Videman T, Lereim I, Hemmingsson P, et al. Changes in hemoglobin values in elite cross-country skiers from 1987–1999. Scand J Med Sci Sports. 2000;10(2):98–102.
32. Manfredini F, Carrabre JE, Litmanen H, et al. Blood tests and fair competition: the biathlon experience. Int J Sports Med. 2003;24(5):352–8.
33. Sottas PE, Robinson N, Saugy M, et al. A forensic approach to the interpretation of blood doping markers. Law Probab Risk. 2008;7(3):191–210.
34. Sottas PE, Robinson N, Saugy M. The athlete’s biological passport and indirect markers of blood doping. Handb Exp Pharmacol. 2010;195:305–26.
35. Sottas PE, Saudan C, Saugy M. Doping: a paradigm shift has taken place in testing. Nature. 2008;455(7210):166.
36. Sottas PE, Robinson N, Fischetto G, et al. Prevalence of blood doping in samples collected from elite track and field athletes. Clin Chem. 2011;57(5):762–9.
37. Vouillamoz M, Thom C, Grisdale R, et al. Anti-doping testing at the 2008 European football championship. Drug Test Anal. 2009;1(11–12):485–93.
38. Stray-Gundersen J, Videman T, Penttila I, et al. Abnormal hematologic profiles in elite cross-country skiers: blood doping or? Clin J Sport Med. 2003;13(3):132–7.
39. Kuipers H, Moran J, Dubravcic-Simunjak S, et al. Hemoglobin level in elite speed skaters from 2000 up to 2005, and its relationship with competitive results. Int J Sports Med. 2007;28(1):16–20.
40. Kuipers H, Moran J, Mitchell DW, et al. Hemoglobin levels and athletic performance in elite speed skaters during the Olympic season 2006. Clin J Sport Med. 2007;17(2):135–9.
41. Sottas PE, Saudan C, Schweizer C, et al. From population- to subject-based limits of T/E ratio to detect testosterone abuse in elite sports. Forensic Sci Int. 2008;174(2–3):166–72.
42. Schumacher YO, Saugy M, Pottgiesser T, et al. Detection of EPO doping and blood doping: the haematological module of the Athlete Biological Passport. Drug Test Anal. 2012;4:846–53.
43. Schroder HF, Gebhardt W, Thevis M. Anabolic, doping, and lifestyle drugs, and selected metabolites in wastewater-detection, quantification, and behaviour monitored by high-resolution MS and MS(n) before and after sewage treatment. Anal Bioanal Chem. 2010;398(3):1207–29.
44. Reid MJ, Langford KH, Grung M, et al. Estimation of cocaine consumption in the community: a critical comparison of the results from three complimentary techniques. BMJ Open. 2012;2(6).
45. Bahrke MS, Yesalis CE. Abuse of anabolic androgenic steroids and related substances in sport and exercise. Curr Opin Pharmacol. 2004;4(6):614–20.
46. Bahrke MS, Yesalis CE, Kopstein AN, et al. Risk factors associated with anabolic-androgenic steroid use among adolescents. Sports Med. 2000;29(6):397–405.
47. Castillo EM, Comstock RD. Prevalence of use of performance-enhancing substances among United States adolescents. Pediatr Clin North Am. 2007;54(4):663–75 (ix–x).
48. Kindlundh AM, Isacson DG, Berglund L, et al. Doping among high school students in Uppsala, Sweden: a presentation of the attitudes, distribution, side effects, and extent of use. Scand J Soc Med. 1998;26(1):71–4.
49. Laure P, Binsinger C. Doping prevalence among preadolescent athletes: a 4-year follow-up. Br J Sports Med. 2007;41(10):660–3 (discussion 3).
50. Sjoqvist F, Garle M, Rane A. Use of doping agents, particularly anabolic steroids, in sports and society. Lancet. 2008;371(9627):1872–82.
51. van Amsterdam J, Opperhuizen A, Hartgens F. Adverse health effects of anabolic-androgenic steroids. Regul Toxicol Pharmacol. 2010;57(1):117–23.
52. vandenBerg P, Neumark-Sztainer D, Cafri G, et al. Steroid use among adolescents: longitudinal findings from Project EAT. Pediatrics. 2007;119(3):476–86.
53. Nilsson S, Baigi A, Marklund B, et al. The prevalence of the use of androgenic anabolic steroids by adolescents in a county of Sweden. Eur J Public Health. 2001;11(2):195–7.
54. Terney R, McLain LG. The use of anabolic steroids in high school students. Am J Dis Child. 1990;144(1):99–103.
55. Papadopoulos FC, Skalkidis I, Parkkari J, et al. Doping use among tertiary education students in six developed countries. Eur J Epidemiol. 2006;21(4):307–13.
56. Wanjek B, Rosendahl J, Strauss B, et al. Doping, drugs and drug abuse among adolescents in the State of Thuringia (Germany): prevalence, knowledge and attitudes. Int J Sports Med. 2007;28(4):346–53.
57. Windsor R, Dumitru D. Prevalence of anabolic steroid use by male and female adolescents. Med Sci Sports Exerc. 1989;21(5):494–7.
58. Yesalis CE, Bahrke MS. Anabolic-androgenic steroids. Current issues. Sports Med. 1995;19(5):326–40.
59. Thevis M, Sauer M, Geyer H, et al. Determination of the prevalence of anabolic steroids, stimulants, and selected drugs subject to doping controls among elite sport students using analytical chemistry. J Sports Sci. 2008;26(10):1059–65.
60. Melnik BC. Androgen abuse in the community. Curr Opin Endocrinol Diabetes Obes. 2009;16(3):218–23.
61. Baker JS, Graham M, Davies B. Gym users and abuse of prescription drugs. J R Soc Med. 2006;99(7):331–2.
62. Baker JS, Graham MR, Davies B. Steroid and prescription medicine abuse in the health and fitness community: a regional study. Eur J Intern Med. 2006;17(7):479–84.
63. Evans NA. Current concepts in anabolic-androgenic steroids. Am J Sports Med. 2004;32(2):534–42.
64. Bolding G, Sherr L, Elford J. Use of anabolic steroids and associated health risks among gay men attending London gyms. Addiction. 2002;97(2):195–203.
65. Da Silva PR, Machado LC Jr, Figueiredo VC, et al. Prevalence of the use of anabolic agents among strength training apprentices in Porto Alegre, RS. Arq Bras Endocrinol Metabol. 2007;51(1):104–10.
66. Graham MR, Davies B, Grace FM, et al. Anabolic steroid use: patterns of use and detection of doping. Sports Med. 2008;38(6):505–25.
67. Striegel H, Simon P, Frisch S, et al. Anabolic ergogenic substance users in fitness-sports: a distinct group supported by the health care system. Drug Alcohol Depend. 2006;81(1):11–9.
68. Tricker R, O’Neill MR, Cook D. The incidence of anabolic steroid use among competitive bodybuilders. J Drug Educ. 1989;19(4):313–25.
69. Kanayama G, Gruber AJ, Pope HG Jr, et al. Over-the-counter drug use in gymnasiums: an underrecognized substance abuse problem? Psychother Psychosom. 2001;70(3):137–40.
70. Petroczi A, Aidman EV, Hussain I, et al. Virtue or pretense? Looking behind self-declared innocence in doping. PLoS One. 2010;5(5):e10457.
71. Petroczi A, Uvacsek M, Nepusz T, et al. Incongruence in doping related attitudes, beliefs and opinions in the context of discordant behavioural data: in which measure do we trust? PLoS One. 2011;6(4):e18804.
72. Striegel H, Ulrich R, Simon P. Randomized response estimates for doping and illicit drug use in elite athletes. Drug Alcohol Depend. 2010;106(2–3):230–2.
73. Secades-Villa R, Fernandez-Hermida JR. The validity of self-reports in a follow-up study with drug addicts. Addict Behav. 2003;28(6):1175–82.
74. Stone AL, Latimer WW. Adolescent substance use assessment: concordance between tools using self-administered and interview formats. Subst Use Misuse. 2005;40(12):1865–74.
75. Goldman B, Bush P, Klatz R. Death in the locker room. United States: Icarus Press; 1984.
76. Connor J, Woolf J, Mazanov J. Would they dope? Revisiting the Goldman dilemma. Br J Sports Med. 2013;47(11):697–700.
77. Lensvelt-Mulders G, Hox J, Van der Heijden P, et al. Meta-analysis of randomized response research: thirty-five years of validation. Sociol Methods Res. 2005;33:319–48.
78. Lensvelt-Mulders G, Hox J, Van der Heijden P. How to improve the efficiency of randomized response designs. Qual Quant. 2005;39:253–65.
79. Pitsch W, Emrich E, Klein M. Doping in elite sports in Germany: results of a www survey. Eur J Sport Soc. 2007;4(2):89–102.
80. Stubbe JH, Chorus AMJ, Frank LE, et al. Prevalence of use of performance enhancing drugs by fitness center members. Drug Test Anal. 2013;6(5):434–8.
81. Simon P, Striegel H, Aust F, et al. Doping in fitness sports: estimated number of unreported cases and individual probability of doping. Addiction. 2006;101(11):1640–4.
82. Seiler S, Beneke R, Halson SL, et al. Is doping-free sport a Utopia? Int J Sports Physiol Perform. 2013;8(1):1–3.
83. Zhong W, Wu H, Li L. Olympics: some facts about Ye Shiwen’s swim. Nature. 2012;488(7412):459.
84. Vayer A. La preuve par 21. 2013 [17 June 2013]; Available from: http://www.alternativeditions.com/la-preuve-par-21/.
85. Savage M. Armstrong in context. 2012 [17 June 2013]; Available from: http://www.phys.washington.edu/users/savage/Cycling/LookingAtTheData/AIC.html.
86. Tucker R, Dugas J. The anatomy of a climb: Contador on the Verbier—its place in Tour climbing “history”; 2009 [17 June 2013]; Available from: http://www.sportsscientists.com/2009/07/tour-2009-contador-climb.html.
87. Noakes TD. Tainted glory—doping and athletic performance. N Engl J Med. 2004;351(9):847–9.
88. Seiler S, De Koning JJ, Foster C. The fall and rise of the gender difference in elite anaerobic performance 1952–2006. Med Sci Sports Exerc. 2007;39(3):534–40.
89. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34(8):513–54.
90. Berthelot G, Tafflet M, El Helou N, et al. Athlete atypicity on the edge of human achievement: performances stagnate after the last peak, in 1988. PLoS One. 2010;5(1):e8800.
91. Berthelot G, Thibault V, Tafflet M, et al. The citius end: world records progression announces the completion of a brief ultra-physiological quest. PLoS One. 2008;3(2):e1552.
92. Lippi G, Banfi G, Favaloro EJ, et al. Updates on improvement of human athletic performance: focus on world records in athletics. Br Med Bull. 2008;87:7–15.
93. Lodewijkx HF, Brouwer B. Some empirical notes on the epo epidemic in professional cycling. Res Q Exerc Sport. 2011;82(4):740–54.
94. El Helou N, Berthelot G, Thibault V, et al. Tour de France, Giro, Vuelta, and classic European races show a unique progression of road cycling speed in the last 20 years. J Sports Sci. 2010;28(7):789–96.
95. Ernst S, Simon P. A quantitative approach for assessing significant improvements in elite sprint performance: has IGF-1 entered the arena? Drug Test Anal. 2013;5(6):384-9.
96. De Rijckaert E. zaak Festina–Het recht van antwoord van dokter Eric Rijckaert [The Festina case—the right to an answer by doctor Eric Rijckaert]. Belgium: Uitgeverij Lannoo NV; 2000.
97. Dekker T. Schoon genoeg [Clean enough]. Amsterdam: Arbeiderspers; 2011.
98. Hamilton T, Coyle D. The secret race—inside the hidden world of the Tour de France: doping, cover-ups, and winning at all costs. USA: Bantam Books; 2012.
99. Millar D, Whittle J. Racing through the dark. London: Orion Books; 2011.
100. Matschiner S, Behr M. Grenzwertig: Aus dem Leben eines Dopingdealers [Threshold-worthy: out of the life of a doping dealer]. Germany: Riva Sportverlag; 2011.
101. Canseco J. Juiced: wild times, rampant’ roids, smash hits, and how baseball got big. USA: William Morrow; 2005.
102. Lentillon-Kaestner V, Carstairs C. Doping use among young elite cyclists: a qualitative psychosociological approach. Scand J Med Sci Sports. 2010;20(2):336–45.
103. Ohl F, Fincoeur B, Lentillon-Kaestner V, et al. The socialization of young cyclists and the culture of doping. Int Rev Sociol Sport. Epub 24 July 2013.
104. Petroczi A, Mazanov J, Nepusz T, et al. Comfort in big numbers: does over-estimation of doping prevalence in others indicate self-involvement? J Occup Med Toxicol. 2008;3:19.
105. Press A. WADA: 1 in 10 may be doping. 2012 [updated 30 May 2013]; Available from: http://espn.go.com/olympics/story/_/id/7550694/wada-says-research-indicates-1-10-athletes-doping.
106. Donovan RJ, Egger G, Kapernick V, et al. A conceptual framework for achieving performance enhancing drug compliance in sport. Sports Med. 2002;32(4):269–84.
107. Morente-Sanchez J, Zabala M. Doping in sport: a review of elite athletes’ attitudes, beliefs, and knowledge. Sports Med. 2013;43(6):395–411.
108. Marclay F, Grata E, Perrenoud L, et al. A one-year monitoring of nicotine use in sport: frontier between potential performance enhancement and addiction issues. Forensic Sci Int. 2011;213(1–3):73–84.
109. Puffer JC. The use of drugs in swimming. Clin Sports Med. 1986;5(1):77–89.
110. SportAccord. Definition of sport. Lausanne, Switzerland 2013 [30 May 2013]; Available from: http://www.sportaccord.com/en/members/definition-of-sport/.